Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Up 44.9% in December

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totaling 368 shares, an increase of 44.9% from the December 15th total of 254 shares. Based on an average daily trading volume, of 3,296 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the shares of the company are short sold. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 3,296 shares, the days-to-cover ratio is presently 0.1 days.

Ascentage Pharma Group International Stock Performance

AAPG stock opened at $27.05 on Monday. The stock has a fifty day moving average of $29.68 and a 200-day moving average of $35.76. Ascentage Pharma Group International has a fifty-two week low of $16.50 and a fifty-two week high of $48.45. The company has a current ratio of 1.54, a quick ratio of 1.53 and a debt-to-equity ratio of 1.31.

Institutional Trading of Ascentage Pharma Group International

A number of institutional investors have recently modified their holdings of the business. Chevy Chase Trust Holdings LLC purchased a new position in Ascentage Pharma Group International in the 2nd quarter valued at approximately $227,000. Tema Etfs LLC purchased a new position in shares of Ascentage Pharma Group International in the second quarter valued at $610,000. Citadel Advisors LLC bought a new stake in shares of Ascentage Pharma Group International during the 3rd quarter valued at $383,000. XY Capital Ltd lifted its holdings in Ascentage Pharma Group International by 224.2% during the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares in the last quarter. Finally, UBS Group AG boosted its stake in Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares during the period.

Analyst Upgrades and Downgrades

A number of analysts recently commented on AAPG shares. Piper Sandler started coverage on Ascentage Pharma Group International in a research report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 price target for the company. Oppenheimer started coverage on Ascentage Pharma Group International in a research report on Thursday, December 4th. They set an “outperform” rating and a $45.00 target price for the company. Truist Financial set a $51.00 target price on Ascentage Pharma Group International in a research note on Monday, November 24th. BTIG Research started coverage on shares of Ascentage Pharma Group International in a research report on Monday, November 10th. They set a “buy” rating and a $50.00 price target for the company. Finally, Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $48.40.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.